If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Download FREE Excerpt
41 Info Graphics
73 Data Graphics
30+ Best Practices
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care
Advanced Biohealing; Allergan; Amylin; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cephalon; EndoPharma; Eisai; Gambro; G.E. Healthcare; Genetech; GlaxoSmithKline; Ironwood Pharma; Kadmon Pharma; Laboratorios Esteve; Lantheus Medical Imaging; Metronic; Merck Sharp and Dohme; Novartis; Novo Nordisk; Onyx Pharma; Pfizer; QLT; Quidel; Shire; Takeda; Theravance; UCB
The report is based on research and information provided by 35 Pharmaceutical and Medical Device executives from 30 different companies.
Also, the study includes both large, established and small, emerging Pharmaceutical and Medical Device companies to provide broadest insights.
MSLs Expected to Work More Regularly with Other Internal Groups: Sales Reps and Professional Relations/Advocacy are the two groups that will be served most regularly (59 and 38%, respectively from survey). Surprisingly, 25% of companies say they do not serve Payer Services, but a number of companies said they have specially trained MSLs to serve this role. Those companies tout it as an important service.
Limited Fear of Losing Access to KOLs: A little more than one-third of companies say the see a high risk of KOL’s home institutions curtailing MSL access to such opinion leaders. Some did point out that some MSLs are becoming “too commercial” in their touch points and that could negatively impact access if it continues.
Corporate Integrity Agreements and Lawsuits Viewed With Minimal Concern: Only 25% of companies see a “high risk” that a CIA or lawsuit will discourage companies from providing services to KOLs and attempting to collaborate with them in the next two years.
Regulatory Bodies Will Make It Harder to Work with or See KOLs: Of all the potential risk factors listed in the survey, this one caused the most alarm. Forty-one percent view a “high risk” and 34% view this as a “medium risk.” Only “KOL's home institution limit their ability to see MSLs” garnered a higher combined risk score.